Leerink downgraded Avidity Biosciences (RNA) to Market Perform from Outperform with a $72 price target after Novartis (NVS) announced an agreement to acquire Avidity for $72 per share in cash.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RNA: